Organon & Co.

NYSE:OGN   12:48:28 PM EDT
-0.34 (-1.10%)
Products, Strategic Combinations

Organon, Cirqle Biomedical Enter Agreement For Investigational Non-Hormonal, On-Demand Contraceptive Candidate

Published: 07/28/2022 11:54 GMT
Organon & Co. (OGN) - Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate.
Organon & Co - Cirqle Will Be Responsible for Conducting Preclinical Studies According to Mutually Agreed Research Plan.
Organon & Co - Organon Will Obtain Exclusive Worldwide Rights to Develop and Commercialize Asset.
Organon & Co - Cirqle is Entitled to Receive a $10 Million Upfront Payment, Potential Milestone Payments of Up to $360 Million and Royalties Based on Net Sales.